Group 1: Industry Development Direction - The company will enhance R&D innovation and improve product quality and production processes to solidify its market position in the raw material drug sector [1] - There will be increased investment in the R&D, production, and sales of chemical drug formulations, gradually extending into the formulation industry chain [1] - This extension aims to better meet customer needs, increase product added value, and enhance market competitiveness for sustainable development [1] Group 2: Market Value Management - The company emphasizes market value management through a series of measures, focusing on core business development and enhancing operational efficiency to drive value growth [2] - Active communication with investors is maintained through performance briefings and interactive platforms to enhance information transparency [2] - A reasonable and sustainable profit distribution plan is in place to create a long-term, stable shareholder value return mechanism [2] Group 3: Product Development Focus - Currently, the company has 17 products under research, covering areas such as antiviral, antidepressant, and lipid-lowering treatments [2] - Key development directions for the year include improving existing product processes to reduce production costs and enhance market competitiveness [2] - Accelerating the transition of existing raw material products to formulations and ensuring smooth commercialization of research products are prioritized to create new business growth points and profit sources [2]

029 浙江海森药业股份有限公司 关于公司董事、高级管理人员减持股份的预披露公告 本公司董事、总经理艾林先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：001367 证券简称：海森药业 公告编号：2025- 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 持有浙江海森药业股份有限公司（以下简称"公司"）股份 6,014,252 股 （占公司总股本的 3.96%）的董事、总经理艾林计划自本公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 6 月 24 日至 2025 年 9 月 23 日）以集中竞 价交易方式或者大宗交易方式减持公司股份 1,472,113 股（占公司总股本的 0.97%）。 公司近日收到董事、总经理艾林先生出具的《关于股份减持计划的告知 函》，根据《上市公司股东减持股份管理暂行办法》《上市公司董事和高级管 理人员所持本公司股份及其变动管理规则》《深圳证券交易所上市公司自律监 管指引第 18 号——股东及董事、高级管理人员减持股份》等相关规定，现将相 关情况公告如下： 一、减持主体的基本情况 截至 ...

Group 1 - The core point of the article is that Haisen Pharmaceutical (001367) announced that its director and general manager, Ai Lin, plans to reduce his holdings by up to 1.4721 million shares, accounting for 0.97% of the company's total share capital, within three months after the announcement [1] - Ai Lin currently holds 3.96% of the company's shares, and the reason for the reduction is personal financial needs [1] - The reduction price will not be lower than the company's initial public offering price [1]

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management, allowing up to RMB 300 million to be invested in low-risk, high-liquidity financial products, ensuring that it does not affect the normal operation of fundraising projects [1][3]. Group 1: Cash Management Implementation - The company has opened dedicated settlement accounts for cash management of raised funds at various securities firms, ensuring compliance with regulations [2]. - The accounts will only be used for the settlement of idle raised funds and will not be used for other purposes [2]. Group 2: Risk Control Measures - The company will adhere to relevant laws and regulations, including the "Regulations on the Supervision of Raised Funds by Listed Companies," to manage cash effectively and disclose information timely [2]. - Measures will be taken to control investment risks, including reporting potential risks and returns to the board's audit committee [3]. Group 3: Impact on the Company - The cash management of idle raised funds will not change the purpose of the funds or harm the interests of the company and its shareholders, ensuring normal business operations [3]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [3].

Core Viewpoint - Zhejiang Haisen Pharmaceutical Co., Ltd. has successfully completed the registration change of its capital and the revision of its Articles of Association, reflecting a change in registered capital from 106.4 million yuan to 51.926 million yuan [2]. Group 1: Company Announcements - The company held meetings on March 26, 2025, and April 25, 2025, to approve the changes in registered capital and the revision of the Articles of Association [2]. - The company has obtained a new business license from the Zhejiang Provincial Market Supervision Administration following the completion of the registration change [2]. Group 2: Business License Details - The new registered capital is 51.926 million yuan, with no other changes to the business license [2]. - The company is classified as a listed other joint-stock company, established on February 18, 1998, with the legal representative being Wang Shiyue [2].

证券代码：001367 证券简称：海森药业 公告编号：2025-028 浙江海森药业股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海森药业股份有限公司（以下简称"公司"）于2025年3月26日召开了 第三届董事会第十二次会议、第三届监事会第十一次会议，审议通过了《关于使 用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投 资项目建设和正常经营的情况下，使用额度不超过人民币30,000万元（含本数） 闲置募集资金进行现金管理，用于购买安全性高、流动性好、风险低的保本型理 财产品。使用期限自公司董事会审议通过之日起12个月，本次额度生效后将覆盖 前次授权额度，在不超过上述额度及决议有效期内，资金可循环滚动使用。具体 内容详见公司于2025年03月28日在《证券时报》《证券日报》《上海证券报》和 巨潮资讯网(www.cninfo.com.cn)披露的《关于部分闲置募集资金和闲置自有资金 进行现金管理的公告》（公告编号：2025-014）。 一、开立募集资金现金管理产品专用结算账户 ...

浙江海森药业股份有限公司 证券代码：001367 证券简称：海森药业 公告编号：2025-027 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海森药业股份有限公司（以下简称"公司"）分别于2024年12月26日和 2025年3月7日召开了第三届董事会第十次会议和2025年第一次临时股东大会，审 议通过了《<公司章程>并办理工商变更登记的议案》，具体内容详见公司于2024 年12月27日在《证券时报》《证券日报》《上海证券报》和巨潮资讯网 (www.cninfo.com.cn)披露的《关于变更注册资本、修订<公司章程>并办理工商变 更登记的公告》（公告编号：2024-047）。 类型：其他股份有限公司（上市） 成立日期：1998年02月18日 公司分别于2025年3月26日和2025年4月25日召开了第三届董事会第十二次 会议和2024年年度股东大会，审议通过了《关于变更注册资本、修订<公司章程> 并办理工商变更登记的议案》，具体内容详见公司于2025年3月28日在《证券时 报》《证券日报》《上海证券报》和巨潮资 ...

Market Overview - As of May 26, the Shanghai Composite Index closed at 3346.84 points, down 1.53 points, with a decline of 0.05% [1] - The Shenzhen Component Index closed at 10091.16 points, down 41.25 points, with a decline of 0.41% [1] - The ChiNext Index closed at 2005.26 points, down 16.24 points, with a decline of 0.80% [1] High Turnover Stocks - A total of 79 A-shares had a turnover rate exceeding 20% on May 26, with notable stocks including: - Haishen Pharmaceutical (001367) with a turnover rate of 62.09% and a closing price of 25.80 yuan, up 2.99% [1] - Wangzi New Materials (002735) with a turnover rate of 61.78% and a closing price of 18.32 yuan, down 3.38% [1] - Xinbang Intelligent (301112) with a turnover rate of 54.40% and a closing price of 40.26 yuan, up 16.16% [1] - Ruichi Intelligent Manufacturing (833781) with a turnover rate of 50.75% and a closing price of 14.04 yuan, up 30.00% [1] Additional High Turnover Stocks - Other notable stocks with high turnover rates include: - Xintiandi (301277) with a turnover rate of 47.91% and a closing price of 14.38 yuan, down 5.95% [1] - Zhongzhou Special Materials (300963) with a turnover rate of 43.06% and a closing price of 34.42 yuan, up 1.77% [1] - Zhongchao Holdings (002471) with a turnover rate of 41.83% and a closing price of 5.18 yuan, up 9.98% [1] - Zhongke Meiling (835892) with a turnover rate of 41.81% and a closing price of 22.69 yuan, up 16.42% [1]

证券代码：001367 证券简称：海森药业 公告编号：2025-026 浙江海森药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 浙江海森药业股份有限公司（以下简称"公司"、"本公司"）股票（证券简 称：海森药业，证券代码：001367）于 2025 年 5 月 22 日、5 月 23 日连续两个 交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的 相关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会对公司相关事项进行了认真核查， 并书面问询了公司控股股东与实际控制人，现就有关情况说明如下： 较大影响的未公开重大信息； 披露的重大事项，或处于筹划阶段的重大事项； 票的行为。 三、关于不存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所股票上市规 则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、 协议等；董事会也未获悉本公司有根据《深圳证券交易所股票上市规则》等有关 规定应予以披露而未披 ...

证券代码：001367 证券简称：海森药业 公告编号：2025-026 浙江海森药业股份有限公司 5、经核查，公司控股股东、实际控制人在股票异动期间不存在买卖公司股 票的行为。 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 浙江海森药业股份有限公司（以下简称"公司"、"本公司"）股票（证券简 称：海森药业，证券代码：001367）于 2025 年 5 月 22 日、5 月 23 日连续两个 交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的 相关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会对公司相关事项进行了认真核查， 并书面问询了公司控股股东与实际控制人，现就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3、近期公司经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 ...